药品注册申请号:019618
申请类型:NDA (新药申请)
申请人:MYLAN SPECIALITY LP
申请人全名:MYLAN SPECIALTY LP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 ROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Yes Yes AB 1987/12/24 1987/12/24 Prescription
002 SFROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Yes No AB 2008/06/20 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2024/07/30 SUPPL-33(补充) Approval Labeling STANDARD
2023/10/24 SUPPL-32(补充) Approval Labeling STANDARD
2022/11/16 SUPPL-30(补充) Approval Labeling STANDARD
2021/11/01 SUPPL-29(补充) Approval Labeling STANDARD
2021/06/25 SUPPL-27(补充) Approval Labeling STANDARD
2020/10/01 SUPPL-26(补充) Approval Labeling STANDARD
2017/07/27 SUPPL-23(补充) Approval Labeling STANDARD
2016/03/24 SUPPL-22(补充) Approval Manufacturing (CMC) PRIORITY
2008/06/20 SUPPL-18(补充) Approval Manufacturing (CMC) N/A
2005/12/29 SUPPL-16(补充) Approval Labeling STANDARD
2002/07/26 SUPPL-15(补充) Approval Manufacturing (CMC) PRIORITY
2001/10/01 SUPPL-13(补充) Approval Labeling STANDARD
1996/07/22 SUPPL-11(补充) Approval Manufacturing (CMC) PRIORITY
1993/11/22 SUPPL-8(补充) Approval Labeling
1992/03/31 SUPPL-6(补充) Approval Manufacturing (CMC) PRIORITY
1992/02/19 SUPPL-7(补充) Approval Labeling
1991/08/20 SUPPL-5(补充) Approval Manufacturing (CMC) PRIORITY
1989/05/24 SUPPL-2(补充) Approval Labeling
1988/11/07 SUPPL-1(补充) Approval Manufacturing (CMC) PRIORITY
1987/12/24 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
002 7645801 2027/07/24 Y Y PDF格式
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:MESALAMINE 剂型/给药途径:ENEMA;RECTAL 规格:4GM/60ML 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019618 001 NDA ROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription Yes Yes AB 1987/12/24 MYLAN SPECIALITY LP
076751 001 ANDA MESALAMINE MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription No No AB 2004/09/17 PADAGIS ISRAEL
019618 002 NDA SFROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription Yes No AB 2008/06/20 MYLAN SPECIALITY LP
216941 001 ANDA MESALAMINE MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription No No AB 2023/05/30 ENCUBE
活性成分:MESALAMINE 剂型/给药途径:ENEMA;RECTAL 规格:4GM/60ML 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
019618 001 NDA ROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription Yes Yes AB 1987/12/24 MYLAN SPECIALITY LP
076751 001 ANDA MESALAMINE MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription No No AB 2004/09/17 PADAGIS ISRAEL
019618 002 NDA SFROWASA MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription Yes No AB 2008/06/20 MYLAN SPECIALITY LP
216941 001 ANDA MESALAMINE MESALAMINE ENEMA;RECTAL 4GM/60ML Prescription No No AB 2023/05/30 ENCUBE
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database